Clinical trials: Small Cell Lung Cancers
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable…
- Trial name
- NeoADAURA (NCT04351555)
- Testing
- Osimertinib, Cisplatin, Carboplatin
- Where
- 158 sites in United States, Austria and 23 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.
- Trial name
- NCT03169738
- Testing
- avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer.
- Trial name
- NCT05899608
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 260 sites in United States, Belgium and 15 more
- Volunteers
- 1,600 people
- Sponsor
- Summit Therapeutics
Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig.
- Trial name
- NCT07843940
- Testing
- Obrixtamig, Pumitamig, Carboplatin
- Where
- 27 sites in United States, Australia and 8 more
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
Non-small-cell Lung Cancer
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer
- Trial name
- NCT00255489
- Testing
- Gefitinib, palliative thoracic radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.
- Trial name
- NCT01137968
- Testing
- imetelstat, Bevacizumab
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Geron Corporation
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
Non Small Cell Lung Cancer
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
- Trial name
- NCT00890825
- Testing
- AZD6244, docetaxel
- Where
- 63 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences
SCLC, Malignant Melanoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA…
- Conditions
- SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
- Trial name
- NCT05130255
- Testing
- GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Y-mAbs Therapeutics
Non-Small Cell Lung Cancer, Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation…
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- NCT06685718
- Testing
- BG-60366
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 33 people
- Sponsor
- BeOne Medicines
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Non-small Cell Lung Cancer
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor…
- Trial name
- NCT04923906
- Testing
- Aumolertinib
- Where
- China
- Volunteers
- 624 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Non Small Cell Lung Cancer
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC…
- Trial name
- ATALANTE-1 (NCT02654587)
- Testing
- OSE2101, Docetaxel, Pemetrexed
- Where
- 78 sites in United States, Czechia and 8 more
- Volunteers
- 219 people
- Sponsor
- OSE Immunotherapeutics
Non Small Cell Lung Cancer
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients…
- Trial name
- NCT05742607
- Testing
- IPH5201 + durvalumab + standard chemotherapy
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- Innate Pharma
Lung Cancer, Non-small-cell Lung Carcinoma
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard chemotherapy treatment.
- Trial name
- NCT00091663
- Testing
- Tarceva (erlotinib HCl)
- Where
- 92 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Small Cell Lung Carcinoma (SCLC)
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent…
- Trial name
- NCT05990738
- Testing
- BI 764532, Topotecan, Single agent chemotherapy
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.